Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis

Journal of Neuroimmunology

Volumn 113, Issue 1, 2001, Pages 109-118

  Goluszko, Elzbieta ^a   Hjelmström, Peter ^b,c   Deng, Caishu ^a   Poussin, Mathilde A ^a,b,c   Ruddle, Nancy H ^b   Christadoss, Premkumar ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Acetylcholine receptors; Autoimmunity; Cytokines; Lymphotoxins; Myasthenia gravis; TNF receptors

Indexed keywords

CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; CYTOKINE; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN M; LYMPHOTOXIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN GENE; MALE; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD86; AUTOANTIBODIES; GENE EXPRESSION; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYMPHOTOXIN-ALPHA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RECEPTORS, CHOLINERGIC; RECEPTORS, TUMOR NECROSIS FACTOR; SPLEEN;

EID: 0035255040     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00420-3     Document Type: Article

References (36)

1. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice
2. Microenvironments in the normal thymus and the thymus in myasthenia gravis
3. T-lymphocyte interferon-gamma receptor binding in patients with myasthenia gravis
4. Muscle acetylcholine receptor loss in murine experimental autoimmune myasthenia gravis: Correlated with cellular, humoral and clinical responses
5. Animal models of myasthenia gravis
6. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin
7. The effect of B cell deficiency on the immune response to acetylcholine receptor and the development of experimental autoimmune myasthenia gravis
8. An approach to the localization of the susceptibility genes for generalized myasthenia gravis by mapping recombinant ancestral haplotypes
9. IFN-alpha therapy is effective in suppressing the clinical experimental myasthenia gravis
10. Myasthenia gravis
11. Neuromuscular junction in myasthenia gravis: Decreased acetylcholine receptors
12. Development and maturation of secondary lymphoid tissues
13. Lymphotoxin-alpha-dependent spleen microenvironment supports the generation of memory B cells and is required for their subsequent antigen-induced activation
14. Myasthenia gravis with thymic hyperplasia is associated with polymorphisms in the tumor necrosis factor region
15. Polymorphism in tumor necrosis factor genes associated with myasthenia gravis
16. Myasthenia gravis muscle antibodies examined by ELISA: IgG and IgM antibodies characterize different patient subgroups
17. Tumour necrosis factor-alpha polymorphism and secretion in myasthenia gravis
18. The role of major histocompatibility complex genes in myasthenia gravis and experimental autoimmune myasthenia gravis pathogenesis
19. Immunohistological patterns of non-neoplastic changes in the thymus in myasthenia gravis
20. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice
21. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis
22. Experimental autoimmune myasthenia gravis induction in B cell-deficient mice
23. Remission rate after thymectomy in myasthenia gravis when the bias of immunosuppressive therapy is eliminated
24. Production and assay of antibodies to acetylcholine receptors
25. Myasthenia gravis
26. Affinity maturation without germinal centres in lymphotoxin-alpha-deficient mice
27. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat
28. IL-2 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease
29. Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravis
30. TNFA and TNFB polymorphisms in myasthenia gravis
31. Postcapillary venules of the lymph node type in myasthenia
32. A critical role for lymphotoxin in experimental allergic encephalomyelitis
33. Experimental autoimmune myasthenia gravis in the mouse
34. Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis
35. Tumour necrosis factor beta gene polymorphisms in myasthenia gravis
36. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis